PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
15 hedge funds and large institutions have $21.2M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.35M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.31M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.58M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$759K |
Top Sellers
PHAS Hedge Fund Activity: Q4 2018 in Review
15 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2018, worth a combined $21.2M.
Buyers outnumbered sellers: 15 funds opened new PHAS positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $13.4M.
- 15 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $21.2M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2018.
- 15 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 0 closed out, a net change of +15 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Wellington Management Group, an estimated $13.4M added.
Based on aggregated 13F filings for Q4 2018.